Literature DB >> 9464618

Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100.

M W Schreurs1, A J de Boer, A Schmidt, C G Figdor, G J Adema.   

Abstract

Melanocyte lineage-specific antigens, like gp100, have been shown to be recognized by tumour-infiltrating lymphocytes isolated from melanoma patients. Therefore these antigens might be used as targets for specific anti-melanoma immunotherapy. To investigate this potential in syngeneic mouse models, we cloned and characterized the murine homologue of gp100 from a B16 murine melanoma cDNA library. The isolated cDNA clone encodes a protein of 626 amino acids, sharing 79.7% sequence homology with human gp100. Expression of murine gp100 was restricted to cells of the melanocyte lineage, as determined by Northern and Western analysis. However, like human gp100, reverse transcription-polymerase chain reaction (RT-PCR) analysis revealed low levels of transcription of the murine gp100 gene in all the cell lines and normal tissues tested. In contrast, murine tyrosinase, another melanocyte differentiation antigen, mimics human tyrosinase expression and did show absolute melanocyte lineage-specific expression. The characterization of murine gp100 will allow investigation of anti-gp100 immune responses in C57BL/6 mice using the syngeneic B16 tumour model and the possible adverse effects of such immunity on normal melanocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464618     DOI: 10.1097/00008390-199712000-00004

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Christine Pulido; Diana Rommelfanger; Feorillo Galivo; Karen Kaluza; Timothy Kottke; Jill Thompson; Alan Melcher; Richard Vile
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

4.  Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Authors:  Katelyn T Byrne; Anik L Côté; Peisheng Zhang; Shannon M Steinberg; Yanxia Guo; Rameeza Allie; Weijun Zhang; Marc S Ernstoff; Edward J Usherwood; Mary Jo Turk
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

5.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 6.  Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.

Authors:  Yoshihiro Hayakawa; Manabu Kawada; Hiroyoshi Nishikawa; Takahiro Ochiya; Hideyuki Saya; Hiroyuki Seimiya; Ryoji Yao; Masahiro Hayashi; Chieko Kai; Akira Matsuda; Tomoki Naoe; Atsushi Ohtsu; Taku Okazaki; Hideo Saji; Masataka Sata; Haruhiko Sugimura; Yuichi Sugiyama; Masakazu Toi; Tatsuro Irimura
Journal:  Cancer Sci       Date:  2016-02       Impact factor: 6.716

7.  Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis.

Authors:  Katrin Echtler; Ildiko Konrad; Michael Lorenz; Simon Schneider; Sebastian Hofmaier; Florian Plenagl; Konstantin Stark; Thomas Czermak; Anca Tirniceriu; Martin Eichhorn; Axel Walch; Georg Enders; Steffen Massberg; Christian Schulz
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.